MY198354A - Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof - Google Patents
Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereofInfo
- Publication number
- MY198354A MY198354A MYPI2017702227A MYPI2017702227A MY198354A MY 198354 A MY198354 A MY 198354A MY PI2017702227 A MYPI2017702227 A MY PI2017702227A MY PI2017702227 A MYPI2017702227 A MY PI2017702227A MY 198354 A MY198354 A MY 198354A
- Authority
- MY
- Malaysia
- Prior art keywords
- estrogen receptor
- pyrido
- tetrahydro
- receptor modulators
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: [Formula I] and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462093929P | 2014-12-18 | 2014-12-18 | |
US201562110998P | 2015-02-02 | 2015-02-02 | |
US201562142077P | 2015-04-02 | 2015-04-02 | |
PCT/EP2015/080119 WO2016097072A1 (en) | 2014-12-18 | 2015-12-17 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
MY198354A true MY198354A (en) | 2023-08-28 |
Family
ID=54850193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2017702227A MY198354A (en) | 2014-12-18 | 2015-12-17 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof |
Country Status (33)
Country | Link |
---|---|
US (3) | US9980947B2 (en) |
EP (2) | EP3233852B1 (en) |
JP (4) | JP6679147B2 (en) |
KR (2) | KR20230113416A (en) |
CN (5) | CN112375077A (en) |
AU (3) | AU2015367509B2 (en) |
BR (1) | BR112017007662B1 (en) |
CA (1) | CA2963736A1 (en) |
CL (2) | CL2017000814A1 (en) |
CO (1) | CO2017003070A2 (en) |
CR (1) | CR20170250A (en) |
DK (1) | DK3233852T3 (en) |
EA (1) | EA032311B1 (en) |
ES (1) | ES2819448T3 (en) |
HK (1) | HK1243074A1 (en) |
HR (1) | HRP20201396T1 (en) |
HU (1) | HUE050466T2 (en) |
IL (5) | IL301960B1 (en) |
LT (1) | LT3233852T (en) |
MA (1) | MA53837A (en) |
MX (3) | MX2017007489A (en) |
MY (1) | MY198354A (en) |
NZ (1) | NZ769496A (en) |
PE (1) | PE20171330A1 (en) |
PH (1) | PH12017501140A1 (en) |
PL (1) | PL3233852T3 (en) |
PT (1) | PT3233852T (en) |
RS (1) | RS60824B1 (en) |
SG (3) | SG10202100799PA (en) |
SI (1) | SI3233852T1 (en) |
TW (3) | TW202323253A (en) |
UA (1) | UA122868C2 (en) |
WO (1) | WO2016097072A1 (en) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116947880A (en) | 2014-06-27 | 2023-10-27 | 诺格拉制药有限公司 | Aryl receptor modulators and methods of making and using the same |
WO2016097071A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
MA53837A (en) | 2014-12-18 | 2021-11-10 | Hoffmann La Roche | TETRAHYDRO-PYRIDO[3,4-B]INDOLES ESTROGEN RECEPTOR MODULATORS AND THEIR USES |
WO2017059139A1 (en) | 2015-10-01 | 2017-04-06 | Olema Pharmaceuticals, Inc. | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS |
JP2019001715A (en) * | 2015-10-30 | 2019-01-10 | 協和発酵キリン株式会社 | Tricyclic compound |
DK3386500T3 (en) | 2015-12-09 | 2022-12-12 | Univ Illinois | BENZOTHIOPHEN-BASED SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATORS |
DK3411034T3 (en) | 2016-02-05 | 2021-01-11 | Inventisbio Inc | SELECTIVE ESTROGEN RECEPTION DECOMPOSITORS AND ITS USES |
PT3416962T (en) | 2016-02-15 | 2021-07-23 | Sanofi Sa | 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators |
TW201803870A (en) | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | Chemical compounds |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
CN109311876B (en) * | 2016-06-16 | 2022-05-03 | 豪夫迈·罗氏有限公司 | Heteroaryl estrogen receptor modulators and uses thereof |
WO2017216280A1 (en) * | 2016-06-16 | 2017-12-21 | F. Hoffmann-La Roche Ag | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
CN107543871A (en) * | 2016-06-29 | 2018-01-05 | 重庆华邦胜凯制药有限公司 | Separation determination Pabuk former times profit cloth intermediate Z1 and its method about material |
CA3028751A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
WO2018019793A1 (en) * | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
HUE057064T2 (en) * | 2016-09-27 | 2022-04-28 | Radius Pharmaceuticals Inc | Rad1901 for use in treating ovarian cancer |
MX2019004685A (en) * | 2016-10-24 | 2019-08-21 | Astrazeneca Ab | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer. |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
WO2018077260A1 (en) * | 2016-10-28 | 2018-05-03 | 山东罗欣药业集团股份有限公司 | Indolo substituted piperidine compound as estrogen receptor degrading agent |
JP6946430B2 (en) * | 2016-11-17 | 2021-10-06 | サノフイSanofi | A novel substituted N- (3-fluoropropyl) -pyrrolidine compound, a method for producing it, and its therapeutic use. |
WO2018108954A1 (en) | 2016-12-12 | 2018-06-21 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol |
EA037533B9 (en) * | 2016-12-16 | 2021-05-27 | Астразенека Аб | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-f]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER |
CN110177554B (en) | 2017-01-06 | 2023-06-02 | G1治疗公司 | Combination therapy for the treatment of cancer |
WO2018130123A1 (en) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | Pentacyclic compound as selective estrogen receptor down-regulator and use thereof |
WO2018138739A1 (en) | 2017-01-27 | 2018-08-02 | Sun Pharma Advanced Research Company Limited | Novel antiestrogenic heterocyclic compounds |
MX2019008438A (en) | 2017-01-30 | 2019-10-30 | Astrazeneca Ab | Estrogen receptor modulators. |
KR20190117582A (en) | 2017-02-10 | 2019-10-16 | 쥐원 쎄라퓨틱스, 인크. | Benzothiophene Estrogen Receptor Modulator |
EP3645001A4 (en) | 2017-06-29 | 2020-12-02 | G1 Therapeutics, Inc. | Morphic forms of git38 and methods of manufacture thereof |
EP3434272A1 (en) | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
ES2912740T3 (en) | 2017-11-14 | 2022-05-27 | Kind Pharmaceutical | Heterocyclic compound and its application in medicine |
EA038160B1 (en) * | 2017-11-30 | 2021-07-15 | Астразенека Аб | Estrogen receptor modulators |
US10519152B2 (en) | 2017-12-21 | 2019-12-31 | Astrazeneca Ab | Compounds and their use in treating cancer |
CN110343101B (en) * | 2018-04-04 | 2022-07-12 | 青岛福沃药业有限公司 | Estrogen receptor degrading agents for the treatment of breast cancer |
SI3810283T1 (en) | 2018-06-21 | 2023-10-30 | F. Hoffmann-La Roche Ag | Solid forms of the tartrate salt of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido(3,4-b)indol-2-yl)-2,2-difluoropropan-1-ol, process for their preparation and methods of their use in treating cancers |
TWI702219B (en) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | Selective estrogen receptor degraders |
CA3111359A1 (en) | 2018-09-07 | 2020-03-12 | Sanofi | Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN113453679A (en) | 2018-12-20 | 2021-09-28 | C4医药公司 | Targeted protein degradation |
US20220233531A1 (en) * | 2019-02-27 | 2022-07-28 | Millennium Pharmaceuticals, Inc. | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors |
KR20220008869A (en) | 2019-05-14 | 2022-01-21 | 누베이션 바이오 인크. | Anticancer Nuclear Hormone Receptor-Targeting Compounds |
WO2020254289A1 (en) * | 2019-06-17 | 2020-12-24 | Ucb Pharma Gmbh | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis |
AU2020311337A1 (en) * | 2019-07-07 | 2022-01-20 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
AU2020326691A1 (en) | 2019-08-06 | 2022-03-03 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
WO2021055749A1 (en) * | 2019-09-19 | 2021-03-25 | Totus Medicines Inc. | Therapeutic conjugates |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
WO2021143816A1 (en) * | 2020-01-16 | 2021-07-22 | 江苏恒瑞医药股份有限公司 | Fused imide derivative, preparation method therefor and medical use thereof |
TW202140448A (en) * | 2020-01-16 | 2021-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Fused cyclic imide derivatives, preparation method and medical use thereof |
WO2021178846A1 (en) * | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
WO2021213358A1 (en) * | 2020-04-21 | 2021-10-28 | 江苏先声药业有限公司 | Boron-containing compounds and application thereof |
MX2022014133A (en) | 2020-05-12 | 2022-11-30 | Genentech Inc | Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor. |
CA3188350A1 (en) | 2020-06-30 | 2022-01-06 | F. Hoffmann-La Roche Ag | Processes for making serd tricyclic compounds having a substituted phenyl or pyridinyl moiety |
CN114105977B (en) * | 2020-08-28 | 2023-09-01 | 先声再明医药有限公司 | Estrogen receptor modulator compounds and uses thereof |
JP2024502270A (en) * | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Estrogen receptor modulators |
CN116744920A (en) * | 2021-02-08 | 2023-09-12 | 贝达药业股份有限公司 | Heteroaryl piperidine derivative, and pharmaceutical composition and application thereof |
WO2023284837A1 (en) * | 2021-07-15 | 2023-01-19 | 四川海思科制药有限公司 | Arylamino derivative estrogen receptor modulator and use thereof |
WO2023083283A1 (en) * | 2021-11-12 | 2023-05-19 | 先声药业有限公司 | Drug combination for treating tumor, and application thereof |
WO2023091550A1 (en) * | 2021-11-18 | 2023-05-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
WO2023125700A1 (en) * | 2021-12-28 | 2023-07-06 | 南京明德新药研发有限公司 | Salt form and crystal form of tetrahydrocyclohepta indazole compound |
TW202400141A (en) | 2022-04-28 | 2024-01-01 | 瑞士商赫孚孟拉羅股份公司 | Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate |
WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
WO2023221122A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
WO2024015506A1 (en) * | 2022-07-14 | 2024-01-18 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
WO2024017131A1 (en) * | 2022-07-21 | 2024-01-25 | 贝达药业股份有限公司 | Heteroarylopiperidine derivative, and pharmaceutical composition and use thereof |
CN115109058B (en) * | 2022-07-27 | 2023-04-07 | 黑龙江中医药大学 | Medicine for treating gastric cancer and preparation method thereof |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
WO2024039860A1 (en) * | 2022-08-19 | 2024-02-22 | Olema Pharmaceuticals, Inc. | 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer |
WO2024039858A1 (en) * | 2022-08-19 | 2024-02-22 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
WO2024042163A1 (en) * | 2022-08-25 | 2024-02-29 | Sanofi | Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof |
WO2024083716A1 (en) | 2022-10-17 | 2024-04-25 | Astrazeneca Ab | Combinations of a serd for the treatment of cancer |
CN115894485B (en) * | 2023-03-03 | 2023-06-27 | 山东绿叶制药有限公司 | Heteroaryl piperidine derivatives, preparation method thereof and application thereof in medicines |
US11773092B1 (en) | 2023-03-27 | 2023-10-03 | King Faisal University | Pyrido[3,4-b]indol-1-one compounds as antibacterial agents |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE398789C (en) | 1923-03-03 | 1924-07-15 | L V Kramolin | Method and device for preventing eavesdropping on telephone and telegraph traffic by means of electrical waves and for multiple traffic by means of electromagnetic waves |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US5206377A (en) | 1991-12-05 | 1993-04-27 | Whitby Research, Inc. | Compounds useful as antiproliferative agents |
EP0620222A3 (en) | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
IL115582A0 (en) * | 1994-10-14 | 1996-01-19 | Lilly Co Eli | Methods for treating resistant tumors |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
DE60111774T2 (en) | 2000-12-08 | 2006-05-04 | Smithkline Beecham Corp. | ANTIBACTERIAL COMPOUNDS |
JP4220779B2 (en) | 2001-02-12 | 2009-02-04 | リリー アイコス リミテッド ライアビリティ カンパニー | Chemical compound |
US6951961B2 (en) | 2002-05-17 | 2005-10-04 | Marina Nikolaevna Protopopova | Methods of use and compositions for the diagnosis and treatment of infectious disease |
TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
EP1618090A1 (en) | 2003-04-11 | 2006-01-25 | Novo Nordisk A/S | 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
EP1670314A4 (en) | 2003-09-05 | 2009-02-25 | Sequella Inc | Methods and compositions comprising diamines as new anti-tubercular therapeutics |
US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
US8076352B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
CN102408425A (en) | 2004-03-15 | 2012-04-11 | Ptc医疗公司 | Carboline derivatives useful in inhibition of angiogenesis and application thereof |
JP2008508356A (en) | 2004-08-02 | 2008-03-21 | スミスクライン ビーチャム コーポレーション | Compounds useful for HPV infection |
WO2007002051A1 (en) | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
AU2006302415B2 (en) | 2005-10-07 | 2012-09-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
KR101315610B1 (en) | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | Inhibitors of bruton's tyrosine kinase |
JP2010523682A (en) | 2007-04-13 | 2010-07-15 | ピーティーシー セラピューティクス,インコーポレーテッド | Administration of carboline derivatives useful for the treatment of cancer and other diseases |
EP2722333A1 (en) | 2008-04-29 | 2014-04-23 | Novartis AG | Spiro-indole derivatives for the treatment of parasitic diseases. |
US9292307B2 (en) | 2008-07-30 | 2016-03-22 | Kyocera Corporation | User interface generation apparatus |
WO2010015815A2 (en) | 2008-08-05 | 2010-02-11 | Summit Corporation Plc | Compounds for the treatment of flaviviral infections |
WO2010015816A2 (en) | 2008-08-06 | 2010-02-11 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
WO2010029313A1 (en) | 2008-09-11 | 2010-03-18 | Summit Corporation Plc. | Antiinfective compounds |
WO2010049678A2 (en) | 2008-10-31 | 2010-05-06 | Summit Corporation Plc | Treatment of energy utilization diseases |
WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
WO2010075286A1 (en) | 2008-12-24 | 2010-07-01 | University Of Washington | MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY |
US20120135089A1 (en) | 2009-03-17 | 2012-05-31 | Stockwell Brent R | E3 ligase inhibitors |
CA2756808A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted indolo-piperidine compounds |
WO2010138685A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
US20120202801A1 (en) * | 2009-05-27 | 2012-08-09 | Liangxian Cao | Methods for treating breast cancer |
WO2010138695A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
WO2010138652A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating kaposi sarcoma |
TWI671297B (en) * | 2009-05-27 | 2019-09-11 | Ptc治療公司 | Methods for treating cancer and non-neoplastic conditions |
US20120157402A1 (en) | 2009-05-27 | 2012-06-21 | Liangxian Cao | Methods for treating brain tumors |
WO2011150162A1 (en) | 2010-05-27 | 2011-12-01 | Ptc Therapeutics, Inc. | Methods for treating viral conditions |
LT2580210T (en) | 2010-06-10 | 2017-07-25 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
UA109688C2 (en) * | 2010-12-16 | 2015-09-25 | Tricyclic PI3K INHIBITORS AND THEIR APPLICATIONS | |
EP2655367B1 (en) | 2010-12-24 | 2016-07-06 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
JP2015500346A (en) | 2011-12-14 | 2015-01-05 | セラゴン ファーマシューティカルズ,インク. | Estrogen receptor modulators and uses thereof |
LT2828256T (en) | 2012-03-23 | 2019-09-25 | Novartis Ag | Chemical process for preparing spiroindolones and intermediates thereof |
CN104508126B (en) | 2012-03-23 | 2017-06-30 | 科德克希思公司 | Biocatalyst and method for synthesizing the derivative of tryptamines and tryptamine analogues |
DE102012209622A1 (en) | 2012-06-08 | 2013-12-12 | Robert Bosch Gmbh | Gear machine with hydrodynamic and hydrostatically mounted journal |
EP2682119A1 (en) | 2012-07-03 | 2014-01-08 | Université Libre de Bruxelles | Aromatic N-heterocycle derivatives for use as medicine |
EP2738173A1 (en) | 2012-11-28 | 2014-06-04 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Heterocyclic compounds as inhibitors of the sodium iodide symporter |
ES2654161T3 (en) | 2013-05-28 | 2018-02-12 | Astrazeneca Ab | Chemical compounds |
JP6389517B2 (en) | 2013-06-19 | 2018-09-12 | セラゴン ファーマシューティカルズ, インク. | Azetidine estrogen receptor modulator and use thereof |
SG11201509508YA (en) | 2013-06-19 | 2015-12-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulator and uses thereof |
US9861594B2 (en) | 2013-10-28 | 2018-01-09 | Drexel University | Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder |
CN105916501A (en) | 2013-12-06 | 2016-08-31 | 豪夫迈·罗氏有限公司 | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
CN106572990A (en) | 2014-03-13 | 2017-04-19 | 豪夫迈·罗氏有限公司 | Therapeutic combinations with estrogen receptor modulators |
MX2016011698A (en) | 2014-03-13 | 2016-12-12 | Hoffmann La Roche | Methods and compositions for modulating estrogen receptor mutants. |
CN116947880A (en) | 2014-06-27 | 2023-10-27 | 诺格拉制药有限公司 | Aryl receptor modulators and methods of making and using the same |
US20160175284A1 (en) | 2014-12-18 | 2016-06-23 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
MA53837A (en) | 2014-12-18 | 2021-11-10 | Hoffmann La Roche | TETRAHYDRO-PYRIDO[3,4-B]INDOLES ESTROGEN RECEPTOR MODULATORS AND THEIR USES |
WO2016097071A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
WO2017059139A1 (en) | 2015-10-01 | 2017-04-06 | Olema Pharmaceuticals, Inc. | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS |
DK3411034T3 (en) | 2016-02-05 | 2021-01-11 | Inventisbio Inc | SELECTIVE ESTROGEN RECEPTION DECOMPOSITORS AND ITS USES |
-
2015
- 2015-12-17 MA MA053837A patent/MA53837A/en unknown
- 2015-12-17 KR KR1020237024959A patent/KR20230113416A/en not_active Application Discontinuation
- 2015-12-17 PL PL15810660T patent/PL3233852T3/en unknown
- 2015-12-17 SG SG10202100799PA patent/SG10202100799PA/en unknown
- 2015-12-17 HU HUE15810660A patent/HUE050466T2/en unknown
- 2015-12-17 LT LTEP15810660.9T patent/LT3233852T/en unknown
- 2015-12-17 SI SI201531344T patent/SI3233852T1/en unknown
- 2015-12-17 CN CN202011079564.0A patent/CN112375077A/en active Pending
- 2015-12-17 ES ES15810660T patent/ES2819448T3/en active Active
- 2015-12-17 SG SG11201704401TA patent/SG11201704401TA/en unknown
- 2015-12-17 TW TW111140973A patent/TW202323253A/en unknown
- 2015-12-17 EP EP15810660.9A patent/EP3233852B1/en active Active
- 2015-12-17 IL IL301960A patent/IL301960B1/en unknown
- 2015-12-17 KR KR1020177016260A patent/KR102559719B1/en active Application Filing
- 2015-12-17 IL IL287326A patent/IL287326B2/en unknown
- 2015-12-17 CN CN202311635326.7A patent/CN117865872A/en active Pending
- 2015-12-17 MX MX2017007489A patent/MX2017007489A/en active IP Right Grant
- 2015-12-17 CR CR20170250A patent/CR20170250A/en unknown
- 2015-12-17 PT PT158106609T patent/PT3233852T/en unknown
- 2015-12-17 CA CA2963736A patent/CA2963736A1/en active Pending
- 2015-12-17 SG SG10201913913VA patent/SG10201913913VA/en unknown
- 2015-12-17 EA EA201791239A patent/EA032311B1/en not_active IP Right Cessation
- 2015-12-17 CN CN202011080367.0A patent/CN112375078B/en active Active
- 2015-12-17 AU AU2015367509A patent/AU2015367509B2/en active Active
- 2015-12-17 CN CN201580069484.8A patent/CN107108611B/en active Active
- 2015-12-17 RS RS20201092A patent/RS60824B1/en unknown
- 2015-12-17 PE PE2017001069A patent/PE20171330A1/en unknown
- 2015-12-17 NZ NZ769496A patent/NZ769496A/en unknown
- 2015-12-17 EP EP20184866.0A patent/EP3760623A1/en active Pending
- 2015-12-17 DK DK15810660.9T patent/DK3233852T3/en active
- 2015-12-17 CN CN202011080390.XA patent/CN112457310A/en active Pending
- 2015-12-17 TW TW104142533A patent/TWI699363B/en active
- 2015-12-17 TW TW109111355A patent/TWI784255B/en active
- 2015-12-17 UA UAA201707527A patent/UA122868C2/en unknown
- 2015-12-17 BR BR112017007662-4A patent/BR112017007662B1/en active IP Right Grant
- 2015-12-17 US US14/972,326 patent/US9980947B2/en active Active
- 2015-12-17 IL IL311006A patent/IL311006A/en unknown
- 2015-12-17 MY MYPI2017702227A patent/MY198354A/en unknown
- 2015-12-17 WO PCT/EP2015/080119 patent/WO2016097072A1/en active Application Filing
- 2015-12-17 JP JP2017532740A patent/JP6679147B2/en active Active
-
2017
- 2017-03-23 IL IL251370A patent/IL251370B/en active IP Right Grant
- 2017-03-29 CO CONC2017/0003070A patent/CO2017003070A2/en unknown
- 2017-04-04 CL CL2017000814A patent/CL2017000814A1/en unknown
- 2017-06-08 MX MX2022007975A patent/MX2022007975A/en unknown
- 2017-06-08 MX MX2020003532A patent/MX2020003532A/en unknown
- 2017-06-16 PH PH12017501140A patent/PH12017501140A1/en unknown
-
2018
- 2018-02-23 HK HK18102605.3A patent/HK1243074A1/en unknown
- 2018-04-17 US US15/955,539 patent/US10966963B2/en active Active
-
2019
- 2019-02-18 CL CL2019000431A patent/CL2019000431A1/en unknown
- 2019-11-14 IL IL270653A patent/IL270653B/en unknown
- 2019-12-10 JP JP2019223278A patent/JP7128169B2/en active Active
-
2020
- 2020-01-21 AU AU2020200407A patent/AU2020200407B2/en active Active
- 2020-09-01 HR HRP20201396TT patent/HRP20201396T1/en unknown
-
2021
- 2021-01-20 AU AU2021200352A patent/AU2021200352B2/en active Active
- 2021-02-25 US US17/185,319 patent/US20230045776A9/en active Pending
-
2022
- 2022-03-07 JP JP2022034691A patent/JP7446348B2/en active Active
-
2023
- 2023-11-29 JP JP2023201538A patent/JP2024028785A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501140A1 (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
MX2021005214A (en) | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS. | |
SA518392101B1 (en) | Benzimidazole Derivatives as Modulators of ROR-GAMMA | |
MX2018011831A (en) | SOLUBLE C5aR ANTAGONISTS. | |
NZ737399A (en) | Ccr2 modulators | |
SG10201907588XA (en) | Androgen Receptor Modulators And Uses Thereof | |
EA033197B1 (en) | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GluN2B RECEPTOR MODULATORS | |
EA033281B1 (en) | Azabenzimidazoles and their use as ampa receptor modulators | |
NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
PH12019501724A1 (en) | Estrogen receptor modulators | |
MX2017013877A (en) | Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators. | |
PH12017501736A1 (en) | Indole derivatives | |
MX2015002514A (en) | Antagonists of chemokine receptors. | |
MX2017013885A (en) | Indolone compounds and their use as ampa receptor modulators. | |
EA202192092A3 (en) | TETRAHYDRO-PYRIDO[3,4-B]INDOL MODULATORS OF ESTROGEN RECEPTORS AND THEIR APPLICATION | |
AR122456A2 (en) | TETRAHYDRO-PYRIDO[3,4-B]INDOLS MODULATORS OF ESTROGEN RECEPTORS AND THEIR USES | |
PH12019502122A1 (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
MX2017008497A (en) | Novel heterocyclic compounds and the use thereof in medicine and in cosmetics. |